PT-141
PT-141 is the peptide bremelanotide, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women and studied in men as well. It works centrally on melanocortin receptors rather than on blood flow, which distinguishes it from PDE5 drugs.
Studied forSexual desire · Arousal
- How it works
- Melanocortin receptor agonist (bremelanotide)
- Status
- FDA-approved
- Half-life
- ~2.7 hours
